Wellington Management Company and Morningside Ventures joined healthcare investment specialists OrbiMed and Vivo Capital to lead a $100 million Series C round for Gracell Biotechnologies.
"We are . . .
Continue Reading With a Free Trial
Unlock this article instantly, along with the rest of our premium content, newsletters and mandate charts.
Already a subscriber? Log in.